Do analysts rate VVOS or MODD?

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 589.66%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Modular Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LFWD or VVOS more profitable?

Lifeward has a net margin of -123.66% compared to Vivos Therapeutics' net margin of -127.70%. Lifeward's return on equity of -243.14% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lifeward -123.66% -243.14% -97.39% Vivos Therapeutics -127.70% -2,325.64% -98.12%

Do analysts rate RVP or VVOS?

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 589.66%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is VVOS or IRIX more profitable?

IRIDEX has a net margin of -6.23% compared to Vivos Therapeutics' net margin of -127.70%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vivos Therapeutics -127.70% -2,325.64% -98.12% IRIDEX -6.23% N/A -11.16%

Does the media prefer VVOS or ICU?

In the previous week, SeaStar Medical had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for SeaStar Medical and 2 mentions for Vivos Therapeutics. SeaStar Medical's average media sentiment score of 0.99 beat Vivos Therapeutics' score of 0.94 indicating that SeaStar Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SeaStar Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.41 -0.01 (-1.65%)

As of 12:53 PM Eastern

Compare

VVOS vs. MODD, LFWD, RVP, IRIX, and ICU

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Modular Medical (MODD), Lifeward (LFWD), Retractable Technologies (RVP), IRIDEX (IRIX), and SeaStar Medical (ICU). These companies are all part of the "medical equipment" industry.

How does Vivos Therapeutics compare to Modular Medical?

Vivos Therapeutics (NASDAQ:VVOS) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 589.66%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Modular Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.94 beat Modular Medical's score of 0.12 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Positive
Modular Medical	Neutral

Vivos Therapeutics has a beta of 6.16, indicating that its share price is 516% more volatile than the broader market. Comparatively, Modular Medical has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Vivos Therapeutics has higher revenue and earnings than Modular Medical. Modular Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.32	-$21.17M	-$2.14	N/A
Modular Medical	N/A	N/A	-$28.24M	-$14.71	N/A

Modular Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Modular Medical's return on equity of -286.34% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Modular Medical	N/A	-286.34%	-216.26%

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Modular Medical shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 7.1% of Modular Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vivos Therapeutics beats Modular Medical on 10 of the 14 factors compared between the two stocks.

How does Vivos Therapeutics compare to Lifeward?

Lifeward (NASDAQ:LFWD) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Lifeward has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.16, indicating that its stock price is 516% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 1 more articles in the media than Lifeward. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Lifeward. Lifeward's average media sentiment score of 1.87 beat Vivos Therapeutics' score of 0.94 indicating that Lifeward is being referred to more favorably in the media.

Company	Overall Sentiment
Lifeward	Very Positive
Vivos Therapeutics	Positive

Lifeward has higher revenue and earnings than Vivos Therapeutics. Lifeward is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	1.02	-$19.91M	-$19.66	N/A
Vivos Therapeutics	$17.44M	0.32	-$21.17M	-$2.14	N/A

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 25.49%. Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 589.66%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

26.8% of Lifeward shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lifeward has a net margin of -123.66% compared to Vivos Therapeutics' net margin of -127.70%. Lifeward's return on equity of -243.14% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Summary

Lifeward and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Retractable Technologies has a net margin of -41.11% compared to Vivos Therapeutics' net margin of -127.70%. Retractable Technologies' return on equity of -17.15% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Retractable Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.16, indicating that its stock price is 516% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for Vivos Therapeutics and 0 mentions for Retractable Technologies. Vivos Therapeutics' average media sentiment score of 0.94 beat Retractable Technologies' score of 0.75 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Positive
Vivos Therapeutics	Positive

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 589.66%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Retractable Technologies has higher revenue and earnings than Vivos Therapeutics. Retractable Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.56	-$7.01M	-$0.21	N/A
Vivos Therapeutics	$17.44M	0.32	-$21.17M	-$2.14	N/A

Summary

Retractable Technologies and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to IRIDEX?

Vivos Therapeutics (NASDAQ:VVOS) and IRIDEX (NASDAQ:IRIX) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

IRIDEX has a net margin of -6.23% compared to Vivos Therapeutics' net margin of -127.70%. IRIDEX's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
IRIDEX	-6.23%	N/A	-11.16%

Vivos Therapeutics has a beta of 6.16, indicating that its stock price is 516% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

In the previous week, Vivos Therapeutics had 1 more articles in the media than IRIDEX. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for IRIDEX. IRIDEX's average media sentiment score of 1.87 beat Vivos Therapeutics' score of 0.94 indicating that IRIDEX is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivos Therapeutics	Positive
IRIDEX	Very Positive

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 589.66%. IRIDEX has a consensus target price of $3.00, suggesting a potential upside of 222.93%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has higher revenue and earnings than Vivos Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.32	-$21.17M	-$2.14	N/A
IRIDEX	$52.58M	0.31	-$4.44M	-$0.19	N/A

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 8.6% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vivos Therapeutics and IRIDEX tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to SeaStar Medical?

Vivos Therapeutics (NASDAQ:VVOS) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Vivos Therapeutics presently has a consensus price target of $2.80, suggesting a potential upside of 589.66%. SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 93.00%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vivos Therapeutics has a net margin of -127.70% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
SeaStar Medical	-828.62%	-146.29%	-96.48%

Vivos Therapeutics has a beta of 6.16, indicating that its share price is 516% more volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

In the previous week, SeaStar Medical had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for SeaStar Medical and 2 mentions for Vivos Therapeutics. SeaStar Medical's average media sentiment score of 0.99 beat Vivos Therapeutics' score of 0.94 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SeaStar Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SeaStar Medical has lower revenue, but higher earnings than Vivos Therapeutics. SeaStar Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.32	-$21.17M	-$2.14	N/A
SeaStar Medical	$1.23M	13.48	-$12.15M	-$4.80	N/A

Summary

Vivos Therapeutics beats SeaStar Medical on 10 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.64M	$3.04B	$6.87B	$12.28B
Dividend Yield	N/A	2.09%	2.68%	8.87%
P/E Ratio	-0.19	19.87	27.22	23.92
Price / Sales	0.32	807.98	581.69	113.21
Price / Cash	N/A	56.84	49.25	59.89
Price / Book	-2.54	4.27	10.72	6.21
Net Income	-$21.17M	$65.46M	$3.59B	$331.73M
7 Day Performance	-6.02%	-3.26%	-2.12%	-2.18%
1 Month Performance	-20.58%	0.68%	2.12%	-1.53%
1 Year Performance	-92.91%	17.63%	24.56%	16.99%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	2.1818 of 5 stars	$0.41 -1.6%	$2.80 +589.7%	-93.2%	$5.64M	$17.44M	N/A	160
MODD Modular Medical	0.4264 of 5 stars	$4.28 -7.8%	N/A	-84.7%	$25.12M	N/A	N/A	20	Short Interest Increase
LFWD Lifeward	2.3603 of 5 stars	$8.45 -3.2%	$10.00 +18.3%	-11.7%	$24.57M	$22.03M	N/A	60	Positive News High Trading Volume
RVP Retractable Technologies	N/A	$0.71 -3.1%	N/A	+2.8%	$21.29M	$37.15M	N/A	240
IRIX IRIDEX	2.0276 of 5 stars	$1.12 flat	$3.00 +167.9%	-11.1%	$19.50M	$52.58M	N/A	120	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MODD, LFWD, RVP, IRIX, and ICU

How does Vivos Therapeutics compare to Modular Medical?

Summary

How does Vivos Therapeutics compare to Lifeward?

Summary

How does Vivos Therapeutics compare to Retractable Technologies?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Summary

How does Vivos Therapeutics compare to SeaStar Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MODD, LFWD, RVP, IRIX, and ICU

How does Vivos Therapeutics compare to Modular Medical?

Do analysts rate VVOS or MODD?

Does the media favor VVOS or MODD?

Which has more volatility & risk, VVOS or MODD?

Which has preferable valuation and earnings, VVOS or MODD?

Is VVOS or MODD more profitable?

Do insiders and institutionals hold more shares of VVOS or MODD?

Summary

How does Vivos Therapeutics compare to Lifeward?

Which has more risk and volatility, LFWD or VVOS?

Does the media favor LFWD or VVOS?

Which has stronger earnings & valuation, LFWD or VVOS?

Do analysts rate LFWD or VVOS?

Do insiders & institutionals hold more shares of LFWD or VVOS?

Is LFWD or VVOS more profitable?

Summary

How does Vivos Therapeutics compare to Retractable Technologies?

Is RVP or VVOS more profitable?

Do insiders and institutionals hold more shares of RVP or VVOS?

Which has more risk & volatility, RVP or VVOS?

Does the media favor RVP or VVOS?

Do analysts rate RVP or VVOS?

Which has higher valuation & earnings, RVP or VVOS?

Summary

How does Vivos Therapeutics compare to IRIDEX?

Is VVOS or IRIX more profitable?

Which has more risk & volatility, VVOS or IRIX?

Does the media prefer VVOS or IRIX?

Do analysts rate VVOS or IRIX?

Which has stronger valuation & earnings, VVOS or IRIX?

Do institutionals and insiders believe in VVOS or IRIX?

Summary

How does Vivos Therapeutics compare to SeaStar Medical?

Do analysts rate VVOS or ICU?

Is VVOS or ICU more profitable?

Which has more risk and volatility, VVOS or ICU?

Does the media prefer VVOS or ICU?

Do institutionals & insiders believe in VVOS or ICU?

Which has better earnings and valuation, VVOS or ICU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools